Literature DB >> 21917962

Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.

Sanath Kumar Janaka1, Tiffany M Lucas, Marc C Johnson.   

Abstract

HIV-1 efficiently forms pseudotyped particles with many gammaretrovirus glycoproteins, such as Friend murine leukemia virus (F-MLV) Env, but not with the related gibbon ape leukemia virus (GaLV) Env or with a chimeric F-MLV Env with a GaLV cytoplasmic tail domain (CTD). This incompatibility is modulated by the HIV-1 accessory protein Vpu. Because the GaLV Env CTD does not resemble tetherin or CD4, the well-studied targets of Vpu, we sought to characterize the modular sequence in the GaLV Env CTD required for this restriction in the presence of Vpu. Using a systematic mutagenesis scan, we determined that the motif that makes GaLV Env sensitive to Vpu is INxxIxxVKxxVxRxK. This region in the CTD of GaLV Env is predicted to form a helix. Mutations in the CTD that would break this helix abolish sensitivity to Vpu. Although many of these positions can be replaced with amino acids with similar biophysical properties without disrupting the Vpu sensitivity, the final lysine residue is required. This Vpu sensitivity sequence appears to be modular, as the unrelated Rous sarcoma virus (RSV) Env can be made Vpu sensitive by replacing its CTD with the GaLV Env CTD. In addition, F-MLV Env can be made Vpu sensitive by mutating two amino acids in its cytoplasmic tail to make it resemble more closely the Vpu sensitivity motif. Surprisingly, the core components of this Vpu sensitivity sequence are also present in the host surface protein CD4, which is also targeted by Vpu through its CTD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917962      PMCID: PMC3209308          DOI: 10.1128/JVI.05171-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes.

Authors:  R L Willey; F Maldarelli; M A Martin; K Strebel
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  A novel gene of HIV-1, vpu, and its 16-kilodalton product.

Authors:  K Strebel; T Klimkait; M A Martin
Journal:  Science       Date:  1988-09-02       Impact factor: 47.728

3.  Topography of murine leukemia virus envelope proteins: characterization of transmembrane components.

Authors:  A Pinter; W J Honnen
Journal:  J Virol       Date:  1983-06       Impact factor: 5.103

4.  Sequences in the cytoplasmic tail of the gibbon ape leukemia virus envelope protein that prevent its incorporation into lentivirus vectors.

Authors:  I Christodoulopoulos; P M Cannon
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1.

Authors:  Masakazu Tanaka; Takaharu Ueno; Tomomi Nakahara; Kenta Sasaki; Akinori Ishimoto; Hiroyuki Sakai
Journal:  Virology       Date:  2003-07-05       Impact factor: 3.616

6.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

7.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.

Authors:  Nanette Van Damme; Daniel Goff; Chris Katsura; Rebecca L Jorgenson; Richard Mitchell; Marc C Johnson; Edward B Stephens; John Guatelli
Journal:  Cell Host Microbe       Date:  2008-03-13       Impact factor: 21.023

8.  Structural criteria for regulation of membrane fusion and virion incorporation by the murine leukemia virus TM cytoplasmic domain.

Authors:  Gwen M Taylor; David Avram Sanders
Journal:  Virology       Date:  2003-08-01       Impact factor: 3.616

9.  Vpu exerts a positive effect on HIV-1 infectivity by down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells.

Authors:  Karine Levesque; Yong-Sen Zhao; Eric A Cohen
Journal:  J Biol Chem       Date:  2003-05-13       Impact factor: 5.157

10.  Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel.

Authors:  Kate Hsu; Jegatheesan Seharaseyon; Peihong Dong; Stephan Bour; Eduardo Marbán
Journal:  Mol Cell       Date:  2004-04-23       Impact factor: 17.970

View more
  8 in total

1.  Retrovirus glycoprotein functionality requires proper alignment of the ectodomain and the membrane-proximal cytoplasmic tail.

Authors:  Sanath Kumar Janaka; Devon A Gregory; Marc C Johnson
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

2.  Sequence Determinants in Gammaretroviral Env Cytoplasmic Tails Dictate Virus-Specific Pseudotyping Compatibility.

Authors:  Yul Eum Song; Grace Y Olinger; Sanath Kumar Janaka; Marc C Johnson
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

3.  Novel Compound Inhibitors of HIV-1NL4-3 Vpu.

Authors:  Carolyn A Robinson; Terri D Lyddon; Hwi Min Gil; David T Evans; Yury V Kuzmichev; Jonathan Richard; Andrés Finzi; Sarah Welbourn; Lynn Rasmussen; N Miranda Nebane; Vandana V Gupta; Sam Ananthan; Zhaohui Cai; Elizabeth R Wonderlich; Corinne E Augelli-Szafran; Robert Bostwick; Roger G Ptak; Susan M Schader; Marc C Johnson
Journal:  Viruses       Date:  2022-04-15       Impact factor: 5.818

4.  Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.

Authors:  Tiffany M Lucas; Sanath K Janaka; Edward B Stephens; Marc C Johnson
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

5.  Functional complementation of a model target to study Vpu sensitivity.

Authors:  Sanath Kumar Janaka; Jared Faurot; Marc C Johnson
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

6.  βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.

Authors:  Yul Eum Song; Daniel Cyburt; Tiffany M Lucas; Devon A Gregory; Terri D Lyddon; Marc C Johnson
Journal:  Viruses       Date:  2018-10-19       Impact factor: 5.048

7.  Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.

Authors:  Marc C Johnson; Terri D Lyddon; Reinier Suarez; Braxton Salcedo; Mary LePique; Maddie Graham; Clifton Ricana; Carolyn Robinson; Detlef G Ritter
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

8.  Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater.

Authors:  Davida S Smyth; Monica Trujillo; Devon A Gregory; Kristen Cheung; Anna Gao; Maddie Graham; Yue Guan; Caitlyn Guldenpfennig; Irene Hoxie; Sherin Kannoly; Nanami Kubota; Terri D Lyddon; Michelle Markman; Clayton Rushford; Kaung Myat San; Geena Sompanya; Fabrizio Spagnolo; Reinier Suarez; Emma Teixeiro; Mark Daniels; Marc C Johnson; John J Dennehy
Journal:  Nat Commun       Date:  2022-02-03       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.